French pharma SaaS startup Biolevate raised a €30M Series A co-led by RAISE France and Orange Ventures, taking its total funding to €36M

Your ability to automate drug development and regulatory submission tasks improves significantly.

Biolevate, a French startup specializing in AI for life sciences, has secured €30 million in a Series A funding round. The round was co-led by RAISE France and Orange Ventures, with significant contributions from MGHIF, Station F, and existing investor EQT Ventures. This funding brings Biolevate's total capital raised to €36 million. The company plans to use this investment to enhance its platform, which focuses on automating scientific and regulatory workflows within the life sciences sector, and to fuel its global expansion efforts. Biolevate was established in Paris by former Dataiku engineers and AI researchers.

This substantial Series A funding highlights a growing investor appetite for AI-driven solutions specifically tailored to the complex and highly regulated life sciences industry. Biolevate's success indicates that specialized vertical AI platforms, capable of streamlining intricate scientific and regulatory processes, are gaining traction. The backing from major players like Orange Ventures and MGHIF suggests confidence in Biolevate's technology and its potential to address critical bottlenecks in pharmaceutical R&D and compliance.

The expansion into international markets funded by this round will likely intensify competition for existing players in the pharma SaaS space. Companies relying on manual or less integrated workflows may face pressure to adopt similar automation technologies to remain competitive. Biolevate's focus on scientific and regulatory workflows positions it to become a key enabler for faster drug discovery and market entry, potentially reshaping operational strategies across the sector.